相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
mTOR links oncogenic signaling to tumor cell metabolism
Jessica L. Yecies et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Francis X. McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Chemoprevention Meets Glucose Control
Jeffrey A. Engelman et al.
CANCER PREVENTION RESEARCH (2010)
Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis
Regan M. Memmott et al.
CANCER PREVENTION RESEARCH (2010)
Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation
Chunyang Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
Kristen Pollizzi et al.
MOLECULAR CANCER (2009)
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
Jingxiang Huang et al.
BIOCHEMICAL JOURNAL (2008)
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Xu Huang et al.
BIOCHEMICAL JOURNAL (2008)
Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and Apoptosis
Umut Ozcan et al.
MOLECULAR CELL (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
John J. Bissler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
DN Franz et al.
ANNALS OF NEUROLOGY (2006)
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
RJ Shaw et al.
SCIENCE (2005)
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
DJ Kwiatkowski et al.
HUMAN MOLECULAR GENETICS (2005)
Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models
L Lee et al.
GENES CHROMOSOMES & CANCER (2005)
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex
H Kenerson et al.
PEDIATRIC RESEARCH (2005)
The LKB1 tumor suppressor negatively regulates mTOR signaling
RJ Shaw et al.
CANCER CELL (2004)
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome
MN Corradetti et al.
GENES & DEVELOPMENT (2004)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
分享论文
